What is the 13F Pro Quality Score for RFL?

13F Pro ranks Rafael Holdings, Inc. (RFL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RFL's current score at https://13fpro.ai/research/RFL (free sign-up required for the full ranking).

Which hedge funds own the most RFL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RFL include GEODE CAPITAL MANAGEMENT,, BlackRock,, DIMENSIONAL FUND ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RFL as soon as new 13F filings post.

Where does 13F Pro source RFL data?

All Rafael Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Rafael Holdings, Inc. files with the SEC under CIK 1713863. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RFL in?

Rafael Holdings, Inc. (RFL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RFL research updated on 13F Pro?

RFL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Rafael Holdings, Inc.(RFL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1713863 RFL stock profile & AI dashboard →

13F Pro Quality Score

21.7/100

Rank #2,655 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

89.3/100

Profitability

1.4/100

Balance Sheet

10.8/100

Earnings Quality

30.0/100

Free Cash Flow

1.2/100

Institutional Flow

1.7/100

Revenue Scale

0.6/100

Dilution Risk

1.7/100

RFL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Rafael Holdings, Inc. (RFL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RFL at 21.7/100 on a 32-signal composite quality model, placing it at rank #2,655 of 2,879 stocks — the bottom half of the AI-ranked universe. RFL scores in the top quartile across revenue growth (89.3). Areas of concern include revenue scale (0.6) and free cash flow (1.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), Rafael Holdings, Inc. reports quarterly revenue of $179.0K, net income of $-4.2M, free cash flow of $-7.3M. Top institutional holders of RFL by reported 13-F value include GEODE CAPITAL MANAGEMENT,, BlackRock,, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. RFL trades on the NYSE exchange and files with the SEC under CIK 1713863. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RFL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rafael Holdings, Inc. directly from SEC EDGAR. Rafael Holdings, Inc.'s 13F Pro composite quality score has ranged between 3 and 27 since 2021, currently 21.7 — an improving long-term trajectory across 20 quarterly and live scoring snapshots.

✦

Fun facts about Rafael Holdings, Inc.

Quirks, history, and lore behind RFL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare and real estate holding company · micro-cap · listed on NYSE American · headquartered in New Jersey.
2
The Numbers
Revenue in the low tens of millions annually — this is not a giant pharma, it's a small holding company with a focused portfolio of assets and investments.
3
The History
Spun off from a larger company around 2018, it inherited a mix of pharmaceutical royalty interests and commercial real estate holdings — an unusual pairing, to say the least.
4
The Secret
Its healthcare arm holds interests tied to cancer treatment drugs, while its real estate side owns properties in Israel and New Jersey — yes, really.
5
The Lore
It has ties to IDT Biologika and oncology-focused assets, and its Israeli real estate connections reflect the background of the family that controls it — the Jonas family.
6
The Giveaway
Named after the Archangel Rafael, this Jonas family-controlled holding company trades under a three-letter ticker and straddles cancer drug royalties and Israeli real estate.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$179.0K

Net Income

Q3 2026

$-4.2M

Free Cash Flow

Q3 2026

$-7.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+44.0% YoY

$917.0KFY 2025

FY21 $802.0KFY22 $410.0KFY24 $637.0KFY25 $917.0K

Net Income

+11.3% YoY

$-30.5MFY 2025

FY21 $-23.1MFY22 $-124.7MFY24 $-34.4MFY25 $-30.5M

Operating Income

+71.6% YoY

$-29.2MFY 2025

FY21 $-28.2MFY22 $-60.5MFY24 $-102.6MFY25 $-29.2M

EPS (Diluted)

+28.3% YoY

$-1.04FY 2025

FY21 $-1.49FY22 $-6.31FY24 $-1.45FY25 $-1.04

Total Assets

+17.8% YoY

$114.1MFY 2025

FY21 $154.1MFY22 $118.3MFY24 $96.8MFY25 $114.1M

Op. Cash Flow

-142.6% YoY

$-18.9MFY 2025

FY21 $-15.6MFY22 $-26.1MFY24 $-7.8MFY25 $-18.9M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$917.0K +44.0%	$637.0K +55.4%	$410.0K -48.9%	$802.0K -83.7%	$4.9M -0.4%	$4.9M
Net Income	$-30.5M +11.3%	$-34.4M +72.4%	$-124.7M -440.6%	$-23.1M -114.5%	$-10.8M -129.1%	$-4.7M
Operating Income	$-29.2M +71.6%	$-102.6M -69.7%	$-60.5M -114.5%	$-28.2M -233.1%	$-8.5M -26.4%	$-6.7M
EPS (Diluted)	$-1.04 +28.3%	$-1.45 +77.0%	$-6.31 -323.5%	$-1.49	—	—
Total Assets	$114.1M +17.8%	$96.8M -18.2%	$118.3M -23.2%	$154.1M +13.0%	$136.3M -4.1%	$142.1M
Operating Cash Flow	$-18.9M -142.6%	$-7.8M +70.1%	$-26.1M -67.2%	$-15.6M -234.4%	$-4.7M -49.0%	$-3.1M

AI Insight: RFL Financial Trends

Rafael remains pre-revenue with persistent operating losses; cash burn stabilizing but debt emerged in Q4 2025.

• Net losses moderated to $4M–$6M in recent quarters (Q2 2026), down from $12M peak in Q3 2025.

• Operating cash outflow averaged $2M–$3M in first half 2025, worsened to $7M–$10M in latter half.

• Equity declined from $94M (Q3 2025) to $75M (Q2 2026) as accumulated losses eroded shareholder value.

⚠ $22M debt appeared in Q4 2025 balance sheet; monitor covenant compliance and cash runway.

⚠ Zero revenue across all eight quarters signals extended clinical/regulatory pathway; no near-term inflection visible.

AI Insight: RFL Ratio Trends

Rafael Holdings remains deeply unprofitable with all efficiency metrics sharply negative; modest recent improvement in ROE and ROA masks persistent capital destruction.

• ROE improved from -51.2% in Q3 2025 to -22.4% in Q2 2026, suggesting recent operational stabilization.

• ROIC remains deeply negative across entire period; Q2 2026 at -28.3% reflects continued value destruction.

• Leverage stable: D/E ratio 0.26–0.29 over last four quarters, avoiding balance-sheet deterioration.

⚠ ROA volatility extreme: swung from -42.4% (Q3 2025) to -18.4% (Q2 2026)—signals underlying operational instability.

⚠ No positive profitability metrics visible across 18-month window; path to breakeven unclear.

Get alerted when RFL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Rafael Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RFL

GEODE CAPITAL MANAGEMENT, LLC
$553.1K442,404 sh
BlackRock, Inc.
$457.0K365,618 sh
DIMENSIONAL FUND ADVISORS LP
$348.6K278,910 sh
IEQ CAPITAL, LLC
$237.4K189,960 sh
CITADEL ADVISORS LLC
$176.3K141,000 sh
WELLS FARGO & COMPANY/MN
$129.2K103,351 sh
RENAISSANCE TECHNOLOGIES LLC
$111.4K89,138 sh
NORTHERN TRUST CORP
$105.0K84,014 sh
STATE STREET CORP
$77.7K62,170 sh
KAHN BROTHERS GROUP INC
$73.2K58,557 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$553.1K	442,404
BlackRock, Inc.	$457.0K	365,618
DIMENSIONAL FUND ADVISORS LP	$348.6K	278,910
IEQ CAPITAL, LLC	$237.4K	189,960
CITADEL ADVISORS LLC	$176.3K	141,000
WELLS FARGO & COMPANY/MN	$129.2K	103,351
RENAISSANCE TECHNOLOGIES LLC	$111.4K	89,138
NORTHERN TRUST CORP	$105.0K	84,014
STATE STREET CORP	$77.7K	62,170
KAHN BROTHERS GROUP INC	$73.2K	58,557

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RFL on your watchlist

Track score changes the day Rafael Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RFL a good stock to buy?

13F Pro's AI-powered analysis of Rafael Holdings, Inc. (RFL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RFL are available on the RFL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RFL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RFL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rafael Holdings, Inc.'s investment landscape.